Biomarin Pharmaceutical Stock Filter Stocks by Fundamentals
BMRN Stock | USD 90.47 0.40 0.44% |
Biomarin Pharmaceutical fundamentals help investors to digest information that contributes to Biomarin Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Biomarin Stock. The fundamental analysis module provides a way to measure Biomarin Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biomarin Pharmaceutical stock.
Biomarin | Shares Owned by Institutions |
Biomarin Pharmaceutical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Biomarin Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Biomarin Pharmaceutical's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Biomarin Pharmaceutical Institutional Holders
Institutional Holdings refers to the ownership stake in Biomarin Pharmaceutical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Biomarin Pharmaceutical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Biomarin Pharmaceutical's value.Shares | Norges Bank | 2023-12-31 | 3.4 M | Elliott Investment Management L.p. | 2023-12-31 | 3 M | Geode Capital Management, Llc | 2023-12-31 | 2.9 M | Hhg Plc | 2023-12-31 | 2.8 M | Bank Of New York Mellon Corp | 2023-12-31 | 2.6 M | Jpmorgan Chase & Co | 2023-12-31 | 2.4 M | Bank Of America Corp | 2023-12-31 | 2.4 M | Nomura Holdings Inc | 2023-12-31 | 2.1 M | Parnassus Investments, Llc | 2023-12-31 | 1.8 M | Primecap Management Company | 2023-12-31 | 18.4 M | Vanguard Group Inc | 2023-12-31 | 18.1 M |
Biomarin Fundamentals
Return On Equity | 0.0351 | ||||
Return On Asset | 0.0163 | ||||
Profit Margin | 0.07 % | ||||
Operating Margin | 0.04 % | ||||
Current Valuation | 17.21 B | ||||
Shares Outstanding | 189.78 M | ||||
Shares Owned By Insiders | 0.84 % | ||||
Shares Owned By Institutions | 99.16 % | ||||
Number Of Shares Shorted | 3.06 M | ||||
Price To Earning | 220.73 X | ||||
Price To Book | 3.54 X | ||||
Price To Sales | 7.23 X | ||||
Revenue | 2.42 B | ||||
Gross Profit | 1.61 B | ||||
EBITDA | 261.98 M | ||||
Net Income | 167.65 M | ||||
Cash And Equivalents | 1.27 B | ||||
Cash Per Share | 6.85 X | ||||
Total Debt | 1.13 B | ||||
Debt To Equity | 0.24 % | ||||
Current Ratio | 5.15 X | ||||
Book Value Per Share | 26.25 X | ||||
Cash Flow From Operations | 159.26 M | ||||
Short Ratio | 2.39 X | ||||
Earnings Per Share | 0.87 X | ||||
Price To Earnings To Growth | 0.76 X | ||||
Target Price | 109.7 | ||||
Number Of Employees | 3.4 K | ||||
Beta | 0.32 | ||||
Market Capitalization | 17.24 B | ||||
Total Asset | 6.84 B | ||||
Retained Earnings | (621.55 M) | ||||
Working Capital | 1.78 B | ||||
Current Asset | 1.09 B | ||||
Current Liabilities | 445.46 M | ||||
Net Asset | 6.84 B |
About Biomarin Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biomarin Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biomarin Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biomarin Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Biomarin Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Biomarin Stock
0.8 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
0.76 | ABBV | AbbVie Inc Financial Report 25th of April 2024 | PairCorr |
0.55 | EWTX | Edgewise Therapeutics Financial Report 9th of May 2024 | PairCorr |
0.55 | HOWL | Werewolf Therapeutics Financial Report 9th of May 2024 | PairCorr |
0.53 | CCCC | C4 TherapeuticsInc Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Biomarin Pharmaceutical Piotroski F Score and Biomarin Pharmaceutical Altman Z Score analysis. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Biomarin Stock analysis
When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Transaction History View history of all your transactions and understand their impact on performance | |
Stocks Directory Find actively traded stocks across global markets | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.98 | Earnings Share 0.87 | Revenue Per Share 12.88 | Quarterly Revenue Growth 0.202 | Return On Assets 0.0163 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.